The authors tracked CD34+ cells (isolation from BM and PB) over time in patients who received gene therapies for Wiskott-Aldrich syndrome (WAS), sickle cell disease (βS/βS) and thalassemia (β0/βE). This evidence concerns the gene CD34 and Wiskott-Aldrich syndrome.